Targeting TDP-43 in sporadic amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatments.
• TDP-43 protein accumulation is a hallmark in 97% of ALS cases, driving disease pathology.
• Understanding TDP-43's role is crucial for developing effective ALS therapies.

Purpose of the Study:

• To review the biological mechanisms of TDP-43 pathology in ALS.
• To explore emerging therapeutic strategies targeting TDP-43.
• To examine advancements in clinical trial design and biomarker development for ALS.

Main Methods:

• Review of current literature on TDP-43 in ALS pathogenesis.
• Analysis of therapeutic strategies targeting TDP-43 dysfunction.
• Evaluation of biomarker development for clinical trial enhancement.

Main Results:

• TDP-43 loss of nuclear function causes RNA missplicing and cryptic exon inclusion, affecting neuronal genes like STMN2 and UNC13A.
• Therapeutic strategies focus on TDP-43 loss-of-function and gain-of-function mechanisms.
• Biomarkers such as neurofilament light chain and cryptic exon peptides aid clinical trial design.

Conclusions:

• Targeting TDP-43 pathways offers potential for ALS treatment.
• Biomarker-driven patient stratification and optimized trial designs are essential for ALS drug development.
• Integrating biological insights with innovative trial methodologies promises to advance ALS therapies.